Name: Fixed Asset Turnover

Definition: Fixed asset turnover shows how well the company’s long-term physical assets — factories, equipment, property — are being used to generate sales. A high ratio means the company’s facilities are productive and efficient. A low ratio might signal underused assets or over-investment in equipment that isn’t driving enough sales.

Interpretation:
• In '2021', MYGN's fixed asset turnover was 5.51, illustrating how efficiently fixed assets are generating revenue. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at 2.05.
• In '2022', MYGN's fixed asset turnover was 4.34, illustrating how efficiently fixed assets are generating revenue. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at 2.03. Industry average declined by 0.02 from previous year.
• In '2023', MYGN's fixed asset turnover was 4.09, illustrating how efficiently fixed assets are generating revenue. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at 1.87. Industry average declined by 0.16 from previous year.
• In '2024', MYGN's fixed asset turnover was 4.75, illustrating how efficiently fixed assets are generating revenue. The increase since '2023' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at 1.82. Industry average declined by 0.05 from previous year.
Overall, MYGN's fixed asset turnover has consistently declined during the past 4 years.

Formula: Fixed Asset Turnover = Net Sales / Net Fixed Assets

Good Range: Ranges from 1 to 5 depending on asset intensity.